Navigation Links
Labopharm to Present Poster on Dose Titration of Once-daily,Tramadol at 3rd International Forum on Pain Medicine

- Article Discussing Pharmacokinetics and Dose Proportionality of Company's Once-Daily Tramadol to be Published in Biopharmaceutics Journal -

LAVAL, QC, June 29, 2007 /PRNewswire-FirstCall/ - Labopharm Inc. today announced that it will present a poster discussing the dose titration of its once-daily formulation of tramadol at the 3rd International Forum on Pain Medicine to be held June 28 to July 1, 2007 in Montreal, Canada.

The poster compares two different titration schedules for Labopharm's once-daily formulation of tramadol in three Phase III clinical trials: a six-day titration to a 300 mg dose (clinical trials MDT3-002 and MDT3-003) and a nine-day titration to a 300 mg dose (clinical trial MDT3-005). The comparison showed that percentage of adverse events and discontinuations due to adverse events was similar regardless of the titration schedule.

These results, in addition to the fact that Labopharm's once-daily tramadol formulation achieves steady state plasma levels after two days, suggest that a shorter titration schedule may be adequate for most patients. A previous study showed that most patients achieve pain control using Labopharm's once-daily tramadol at a dose of 200 mg. The data in this poster suggest that, for most patients, after starting with a dose of 100 mg for two days, the therapeutic dose of 200 mg could be achieved after two days without increased risk of side effects. If a patient requires a higher dose (300 mg), the therapeutic dose could be achieved after six days of titration (100 mg for 2 days; 200 mg for 3 days then 300 mg on the 6th day) without increased risk of side effects.

"The results of the comparison of titration periods reviewed in the poster suggest that patients may benefit from rapid titration to optimal analgesia without increased risk of side effects using our product," said James R. Howard-Tripp, President and Chief Executive Officer, Labopharm
'"/>




Page: 1 2 3

Related medicine technology :

1. The Past, Present and Future of HLA Typing
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
10. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:10/25/2014)... --  Metanome, Inc. , a Houston ... was the genomic sequencing provider for Seres Health,s ( ... of SER 109, an Ecobiotic® therapeutic for the treatment ... (CDI). Metanome has provided genomic sequencing services ... Such genomic characterization has enabled the study of the ...
(Date:10/25/2014)... 2014 Best Practices designed the Medical ... a forum for sharing insights about the key ... mechanism for creating and sharing solutions through three ... from the Medical Affairs Consortium survey. ... the first roundtable of the 2014-2015 Medical Affairs ...
(Date:10/22/2014)... 22, 2014  Rescheduling of hydrocodone combination products ... pain market, according to a new primary market ... providing market research and consultation exclusively in the ... http://photos.prnewswire.com/prnh/20141021/153440 In August, ... combination products from Schedule III to Schedule II ...
Breaking Medicine Technology:Metanome Selected as Metagenomics Provider for Seres Health Clinical Trial 2Strong Participation in Best Practices' Medical Affairs Consortium Survey 2Hydrocodone: Rescheduled, Repositioned & Reinvented 2Hydrocodone: Rescheduled, Repositioned & Reinvented 3
... COLLEGEVILLE, Pa., March 30, 2007 /PRNewswire-FirstCall/ --,Wyeth ... Inc. and Lundbeck A/S presented clinical study,results ... this,week. Safety analyses suggest bifeprunox, an investigational,treatment ... with a favorable weight and lipid profile, ...
... is STD Awareness Month: Time to Pay Attention ... 2007 /PRNewswire/ -- During,National Sexually Transmitted Disease (STD) ... awareness of, and,testing for, trichomoniasis (also known as ... States. Awareness of the condition,remains low, despite the ...
Cached Medicine Technology:Safety Analyses of Clinical Data for Bifeprunox in Patients with,Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar,to Placebo 2Safety Analyses of Clinical Data for Bifeprunox in Patients with,Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar,to Placebo 3Safety Analyses of Clinical Data for Bifeprunox in Patients with,Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar,to Placebo 4Safety Analyses of Clinical Data for Bifeprunox in Patients with,Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar,to Placebo 5Safety Analyses of Clinical Data for Bifeprunox in Patients with,Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar,to Placebo 6Trichomoniasis: Most Common Curable STD in U.S. Affects 7.4 Million,Annually 2Trichomoniasis: Most Common Curable STD in U.S. Affects 7.4 Million,Annually 3
(Date:10/25/2014)... October 25, 2014 TASC (Total ... and other benefits account management services, announces the ... employers save on taxes, reduce administrative workload, and ... tax savings and the efficient handling of complex, ... Suite that best meets their goals and objectives. ...
(Date:10/25/2014)... 2014 The federal judge overseeing ... ) filed against Boston Scientific Corp. in the ... Southern District of West Virginia has denied a ... in a group of cases filed on behalf ... October 21st, U.S. District Judge Joseph R. Goodwin ...
(Date:10/25/2014)... 2014 (HealthDay News) -- Not getting the right amount ... a new study suggests. Those who sleep less ... per night may be more prone to developing the ... report. The study authors concluded that duration and quality ... patients with inflammatory bowel diseases. "Both short and ...
(Date:10/25/2014)... (HealthDay News) -- October,s shorter, darker days can trigger ... according to an expert. People affected by ... tired, lack motivation and even have trouble getting out ... suicide, said Dr. Angelos Halaris, a professor in the ... Chicago Stitch School of Medicine. "Seasonal affective disorder ...
(Date:10/22/2014)... Isabel Healthcare will participate ... (ASAHP) Conference on October 22-24 in Las Vegas, NV. ... a panel discussion on Technology in Health Professions Education ... a diagnostic decision support tool and clinical education platform ... students and clinical learners. The Isabel tools help clinicians ...
Breaking Medicine News(10 mins):Health News:TASC’s New Suites Offer Tax Savings and Protection 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 4Health News:Sleep Duration Linked to Ulcerative Colitis Risk in Study 2Health News:Dark Days Here for Folks With Seasonal Depression 2Health News:Isabel Healthcare to Participate in The Association of Schools of Allied Health Professions (ASAHP) 2014 Conference 2
... for estrogen-sensitive tumor types, study found , , SUNDAY, April ... amounts, increases the risk of breast cancer and particularly ... shows. , The findings, expected to be presented Sunday ... Cancer Research, in San Diego, are followed by a ...
... Spectrometer is suitable for use in ... potentially explosive atmospheres, PITTSBURGH, April ... The MAX300-IGX Industrial Mass Spectrometer,is suitable for use in potentially ... obtained ATEX,approval for installations in Zone 1 areas. The MAX300-IGX ...
... the University of Pennsylvania School of Medicine and Abramson ... the American Association for Cancer Research that combining two ... lines. The team is currently designing a trial to ... is resistant to many chemotherapies and to cell-death inducing ...
... Calif., April 12 Over 300,healthcare workers at Coastal ... SEIU United Healthcare Workers - West (UHW) in a,secret-ballot ... "Uniting with thousands of other caregivers as a ... difference on the things that matter most," said,Ruth Calderon, ...
... YMCA Healthy Kids Day Saturday, April 12 ... Calif., April 11 The Mt. Diablo Region,YMCA will join ... Kids Day on Saturday, April 12 from 9 a.m. to ... Irvin Deutscher Family YMCA.,An opportunity for kids and families to ...
... researchers got paid but more upset when they owned ... volunteers in clinical studies aren,t overly concerned if researchers ... trust, suggests a U.S. study. , "Though peoples, willingness ... not suffer substantially based on the types of financial ...
Cached Medicine News:Health News:Drinking May Raise Breast Cancer Risk 2Health News:Extrel CMS Announces ATEX Approval for Process Mass Spectrometer 2Health News:Penn researchers find targeted therapy combination overcomes treatment resistance in liver cancer 2Health News:Coastal Communities Hospital Workers Join United Healthcare Workers 2Health News:The Mt. Diablo Region YMCA Invites Families to 'Put Play in Your Day' and Bring Healthy Habits Home During the Nation's Largest Health Day for Children and Families 2Health News:The Mt. Diablo Region YMCA Invites Families to 'Put Play in Your Day' and Bring Healthy Habits Home During the Nation's Largest Health Day for Children and Families 3Health News:Clinical Trial Volunteers Uneasy About Some Financial Ties 2
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Medicine Products: